A Phase 1B, Randomized, Placebo-Controlled, Double-Blinded, Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single-Daily Doses of SQ109 in Normal, Healthy Male and Female Volunteers.

Trial Profile

A Phase 1B, Randomized, Placebo-Controlled, Double-Blinded, Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single-Daily Doses of SQ109 in Normal, Healthy Male and Female Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jun 2011

At a glance

  • Drugs SQ 109 (Primary)
  • Indications Tuberculosis
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Feb 2010 Actual patient number (10) added as reported by ClinicalTrials.gov.
    • 13 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Feb 2010 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top